PE20231069A1 - Compuestos para su uso en el tratamiento de la infeccion por coronavirus - Google Patents
Compuestos para su uso en el tratamiento de la infeccion por coronavirusInfo
- Publication number
- PE20231069A1 PE20231069A1 PE2022001871A PE2022001871A PE20231069A1 PE 20231069 A1 PE20231069 A1 PE 20231069A1 PE 2022001871 A PE2022001871 A PE 2022001871A PE 2022001871 A PE2022001871 A PE 2022001871A PE 20231069 A1 PE20231069 A1 PE 20231069A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- treatment
- covid
- nrb
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382815 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| PCT/EP2021/055137 WO2021175826A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in the treatment of coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231069A1 true PE20231069A1 (es) | 2023-07-17 |
Family
ID=74797953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001871A PE20231069A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en el tratamiento de la infeccion por coronavirus |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230158102A1 (https=) |
| EP (1) | EP4114436A1 (https=) |
| JP (1) | JP2023517295A (https=) |
| KR (1) | KR20220151181A (https=) |
| CN (1) | CN115666615A (https=) |
| AU (1) | AU2021232534A1 (https=) |
| BR (1) | BR112022017008A2 (https=) |
| CA (1) | CA3169791A1 (https=) |
| CL (1) | CL2022002398A1 (https=) |
| CO (1) | CO2022014115A2 (https=) |
| IL (1) | IL296066A (https=) |
| MX (1) | MX2022010922A (https=) |
| PE (1) | PE20231069A1 (https=) |
| PY (1) | PY2117315A (https=) |
| TW (1) | TW202144380A (https=) |
| UY (1) | UY39108A (https=) |
| WO (1) | WO2021175826A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021231521A1 (en) * | 2020-03-02 | 2022-10-06 | Pharma Mar, S.A. | PLD for use in combination in the treatment of coronavirus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| CA2405779A1 (en) | 2000-04-07 | 2001-10-18 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| US7605135B2 (en) * | 2003-11-10 | 2009-10-20 | The University Of Hong Kong | Baicalin as a treatment for SARS infection |
| JP2012512839A (ja) * | 2008-12-19 | 2012-06-07 | ファルマ、マール、ソシエダード、アノニマ | 抗腫瘍性化合物 |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
-
2021
- 2021-03-02 US US17/908,524 patent/US20230158102A1/en active Pending
- 2021-03-02 CA CA3169791A patent/CA3169791A1/en active Pending
- 2021-03-02 TW TW110107291A patent/TW202144380A/zh unknown
- 2021-03-02 CN CN202180018709.2A patent/CN115666615A/zh active Pending
- 2021-03-02 KR KR1020227034222A patent/KR20220151181A/ko active Pending
- 2021-03-02 PE PE2022001871A patent/PE20231069A1/es unknown
- 2021-03-02 JP JP2022552932A patent/JP2023517295A/ja active Pending
- 2021-03-02 BR BR112022017008A patent/BR112022017008A2/pt unknown
- 2021-03-02 AU AU2021232534A patent/AU2021232534A1/en active Pending
- 2021-03-02 WO PCT/EP2021/055137 patent/WO2021175826A1/en not_active Ceased
- 2021-03-02 UY UY0001039108A patent/UY39108A/es unknown
- 2021-03-02 PY PY202102117315A patent/PY2117315A/es unknown
- 2021-03-02 MX MX2022010922A patent/MX2022010922A/es unknown
- 2021-03-02 IL IL296066A patent/IL296066A/en unknown
- 2021-03-02 EP EP21708649.5A patent/EP4114436A1/en active Pending
-
2022
- 2022-09-02 CL CL2022002398A patent/CL2022002398A1/es unknown
- 2022-09-30 CO CONC2022/0014115A patent/CO2022014115A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220151181A (ko) | 2022-11-14 |
| UY39108A (es) | 2021-09-30 |
| JP2023517295A (ja) | 2023-04-25 |
| CN115666615A (zh) | 2023-01-31 |
| PY2117315A (es) | 2022-05-10 |
| MX2022010922A (es) | 2022-09-29 |
| AU2021232534A1 (en) | 2022-10-06 |
| TW202144380A (zh) | 2021-12-01 |
| US20230158102A1 (en) | 2023-05-25 |
| BR112022017008A2 (pt) | 2022-10-11 |
| CO2022014115A2 (es) | 2022-11-18 |
| IL296066A (en) | 2022-11-01 |
| CL2022002398A1 (es) | 2023-06-30 |
| EP4114436A1 (en) | 2023-01-11 |
| CA3169791A1 (en) | 2021-09-10 |
| WO2021175826A1 (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240765A1 (es) | Compuestos para la inhibicion de nlrp3 y usos de estos | |
| PE20211781A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| ECSP077417A (es) | Nuevos derivados de aminopiridina que tienen acción inhibitoria selectiva de la aurora a | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR109295A1 (es) | Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR060994A1 (es) | Derivados de triazolopirazina | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| PE20171648A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb | |
| AR061581A1 (es) | Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c. | |
| AR073687A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
| AR083946A1 (es) | Metodos de tratamiento con inhibidores selectivos de bcl-2 | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| AR082633A1 (es) | Analogos de tetraciclina | |
| AR076176A1 (es) | Derivados de amida de pirazol (3,2-c) esteroides con actividad agonista del receptor de glucocorticoesteroides | |
| AR126612A1 (es) | Compuestos de heteroarilo para el tratamiento de la enfermedad de huntington | |
| PE20221006A1 (es) | Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| AR081261A1 (es) | Metodos para tratar afecciones virales | |
| AR062405A1 (es) | Derivados de isoindol | |
| PE20230412A1 (es) | Compuestos para su uso en afecciones inflamatorias |